US diagnostics manufacturers asked to provide more point-of-care data ahead of clinic & GP use
This article was originally published in Clinica
The US FDA is proposing that diagnostics manufacturers provide substantially more data on how well their laboratory tests perform in the point-of-care setting before the products can be used by healthcare personnel in community clinics and physician offices.
You may also be interested in...
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.
The US Food and Drug Administration posted two device-related closeout letters in November.
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.